Pfizer signs $340 million licensing pact with GlycoMimetics

10/11/2011 | American City Business Journals

GlycoMimetics entered a global licensing agreement with Pfizer for GMI-1070, an experimental treatment for vaso-occlusive crisis in patients with sickle cell disease. The deal calls for GlycoMimetics to complete the drug's Phase II study, then turn over further development and commercialization to Pfizer. GlycoMimetics is entitled to upfront, milestone and royalty payments worth as much as $340 million.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT